The Effects of Commercially Available Preservative-Free FDA-Approved Triamcinolone (Triesence (R)) on Retinal Cells in Culture
Contribuinte(s) |
UNIVERSIDADE DE SÃO PAULO |
---|---|
Data(s) |
18/04/2012
18/04/2012
2011
|
Resumo |
Purpose: To evaluate the effects of Triesence (R) (TRI), a new preservative-free triamcinolone approved by the U. S. Food and Drug Administration (FDA) for intraocular use, on human retina pigment epithelial (ARPE-19) and rat neurosensory (R28) cells in culture. Methods: ARPE-19 and R28 cell cultures were treated 24 h with 1,000, 500, 200, or 100 mu g/mL of crystalline (cTRI) or 1,000, 500, or 200 mu g/mL of solubilized (sTRI). TRI was solubilized by centrifuging the drug, discarding the supernatant containing the vehicle and then resuspending the drug pellet in an equivalent amount of Dimethyl sulfoxide to achieve the same concentration as the commercial preparation. Percentage of cell viability (CV) was evaluated by a trypan blue dye-exclusion assay. The mitochondrial membrane potential (Delta Psi m) was analyzed with the JC-1 assay. The caspase-3/7 activity was measured by a fluorochrome assay. Results: In the ARPE-19 cultures, the cTRI caused a decrease in CV at 1,000 mg/mL (13.03 +/- 6.51; P < 0.001), 500 mu g/mL (28.87 +/- 9.3; P < 0.001), 200 mu g/mL (54.93 +/- 5.61; P < 0.001), and 100 mu g/mL (82.53 +/- 0.65; P < 0.005) compared with the untreated controls (96.98 +/- 0.16). In R28 cultures, the cTRI treatment also reduced CV values significantly (P < 0.001) for the 1,000 mu g/mL (22.73 +/- 2.44), 500 mu g/mL (34.63 +/- 1.91), 200 mu g/mL (58.70 +/- 1.39), and 100 mu g/m (75.33 +/- 2.47) compared with the untreated controls (86.08 +/- 3.54). Once the TRI was solubilized (sTRI), the CV and Delta Psi m remained similar to the untreated controls for both ARPE-19 and R28 cells. The sTRI treatment with 1,000, 500, and 200 mu g/mL increased in caspase-3/7 activity in ARPE-19 cells (P < 0.01) and in R28 cells (P < 0.05) compared with dimethyl sulfoxide equivalent controls. Conclusion: The crystalline form of TRI (cTRI) can cause a significant decrease in CV to cultured retinal cells. Once the TRI is solubilized (sTRI), at the same concentrations, the cells remain viable with no decrease in CV or Delta Psi m. The sTRI can, however, increase caspase-3/7 activity, thus suggesting some degree of apoptosis. Pan-American Association of Ophthalmology Foundation Discovery Eye Foundation Iris and B. Gerald Cantor Foundation Gilbert Foundation Lincy Foundation Ko Family Foundation Research to Prevent Blindness Foundation |
Identificador |
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, v.27, n.2, p.143-150, 2011 1080-7683 http://producao.usp.br/handle/BDPI/15240 10.1089/jop.2010.0143 |
Idioma(s) |
eng |
Publicador |
MARY ANN LIEBERT INC |
Relação |
Journal of Ocular Pharmacology and Therapeutics |
Direitos |
closedAccess Copyright MARY ANN LIEBERT INC |
Palavras-Chave | #PIGMENT EPITHELIAL-CELLS #DIABETIC MACULAR EDEMA #VEHICLE BENZYL ALCOHOL #INTRAVITREAL TRIAMCINOLONE #IN-VITRO #INTRAOCULAR-PRESSURE #ACETONIDE INJECTION #TOXICITY #ENDOPHTHALMITIS #KENALOG #Ophthalmology #Pharmacology & Pharmacy |
Tipo |
article original article publishedVersion |